Skip to content
-
Subscribe to our newsletter & never miss our best posts. Subscribe Now!
Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

Itfy.in

At Itfy, we are dedicated to revolutionizing the way you receive news. Our mission is to provide timely, accurate, and personalized news updates using cutting-edge AI technology. Stay informed, stay ahead with us.

  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
  • Home
  • News Updates
    • Latest News
    • Entertainment News
    • Northeast News
  • Technology
    • Digital Transformation
    • Artificial Intelligence
    • Machine Learning
    • Generative AI
    • Cybersecurity
  • Education & Growth
    • Education
    • Lifelong Learning
    • Parenting
    • Career Growth
  • Startup & Entrepreneurship
    • Remote Work
    • Startups
    • Digital Marketing
    • Social Media
    • Entrepreneurship
    • Lean Thinking
    • Personal Finance
  • Climate Justice
    • Climate Tech
  • Health & Wellness
    • Mental Health
  • Tourism
Close

Search

  • https://www.facebook.com/
  • https://twitter.com/
  • https://t.me/
  • https://www.instagram.com/
  • https://youtube.com/
Subscribe
Home/News/Revolutionizing Treatment: Pfizer, AstraZeneca, and Merck Champion Groundbreaking Alternatives to Chemotherapy
News

Revolutionizing Treatment: Pfizer, AstraZeneca, and Merck Champion Groundbreaking Alternatives to Chemotherapy

By adminitfy
June 17, 2025 3 Min Read

Antibody-drug conjugates (ADCs) are emerging as promising alternatives to traditional chemotherapy in cancer treatment. These targeted medicines deliver powerful chemotherapy agents directly to cancer cells while minimizing harm to healthy cells, marking a significant advancement in oncology. Major pharmaceutical companies like AstraZeneca, Daiichi Sankyo, Pfizer, and Merck are investing billions into the development of ADCs, hoping to transform cancer therapies and potentially replace more traditional approaches that often come with severe side effects.

Despite their potential, experts caution that ADCs may not fully replace chemotherapy in the near future. Dr. John Heymach, chair of thoracic and head/neck medical oncology at MD Anderson Cancer Center, expressed concern that initial expectations for ADCs have yet to be fully realized. “There’s clearly room for improvement,” he noted, highlighting the ongoing need for refinement in these treatments.

Some companies are reporting that ADCs have succeeded in replacing chemotherapy in specific scenarios. David Fredrickson from AstraZeneca remarked, “We are leading the way towards establishing ADCs as a precision-based approach to replace classic chemotherapy.” Recent presentations at the 2025 American Society of Clinical Oncology annual meeting showcased promising data for existing and experimental ADCs, suggesting a shift in the standards of cancer care.

Since the introduction of the first ADC in 2000, over a dozen have gained U.S. approval, and hundreds more are under development. High-profile acquisitions, such as Pfizer’s $43 billion purchase of Seagen in 2023, underscore the soaring interest in this drug class. Forecasts project the ADC market could reach $31 billion out of a $375 billion global cancer market by 2028.

However, challenges remain. Certain treatments have been known to prematurely release their chemotherapy payloads into the bloodstream, affecting healthy cells and leading to adverse effects. Experts emphasize the importance of adequately identifying cancer-specific proteins to target and discovering new payloads that maximize effectiveness while minimizing toxicity.

New ADCs, such as Enhertu from AstraZeneca and Daiichi Sankyo, represent the forefront of innovation. Enhertu boasts the ability to deliver more chemotherapy per dose and employs a smart linker designed to release drugs solely within tumors. Approved treatments for specific breast, lung, and gastric cancers are showing significant sales potential, with increasing interest in extending their applications.

Data from recent clinical trials suggests that dropping conventional chemotherapy in favor of ADCs can lead to enhanced efficacy and safety. Gilead’s Trodelvy, for instance, has shown promising results in aggressive breast cancer types, reinforcing the belief that ADCs may become the preferred treatment option.

Despite setbacks, including Gilead’s withdrawal of Trodelvy from the bladder cancer market following underwhelming trial results, drugmakers continue to converge on ADCs as a transformative approach to cancer therapy. Lessons learned from previous failures have prompted refocused efforts, improving dosing strategies and investigating potential combinations with existing therapies.

Innovative approaches to ADC development are also underway. AbbVie has garnered approval for an ADC targeting the protein c-Met, indicating its commitment to exploring new therapeutic pathways. Meanwhile, GSK’s reapproved Blenrep demonstrates that strategic adjustments can lead to improved outcomes in previously challenging therapies.

The collaborative landscape within ADC research is dynamic, with companies vying to create enhanced formulations that deliver better results. Combining ADCs with immune checkpoint inhibitors may create synergistic effects, enabling a powerful one-two punch against cancer. Pfizer’s Chief Scientific Officer Chris Boshoff highlighted that these combinations could result in increased response rates and improved survival outcomes.

As the ADC field evolves, industry leaders and researchers remain hopeful about integrating these therapies into broader cancer treatment regimens, potentially redefining standards in oncology for years to come.

Original Source: https://www.cnbc.com/2025/06/17/adc-cancer-drugs-pfizer-astrazeneca-merck-bet-on-chemo-replacement.html
Category :
Tags:
Publish Date: 2025-06-17 18:01:00

Author

adminitfy

Follow Me
Other Articles
Previous

Urgent Wake-Up Call: Transforming the Future of Global Aviation

Next

JetBlue Halts More Flights: Unraveling the Uncertain Path to Break-Even by 2025

No Comment! Be the first one.

Leave a Reply Cancel reply

You must be logged in to post a comment.

Search...

Recent Posts

  • Voyager 1 Reaches Historic One Light-Day Distance Milestone
    Voyager 1 Reaches Historic One Light-Day Distance Milestone
    by adminitfy
    November 22, 2026
  • Empowering Northeast India: CII’s CSR Connect Event Ignites Social Development
    by adminitfy
    July 3, 2024
  • Urgent Crisis: Northeast on High Alert as Death Toll Tragically Rises in Assam
    by adminitfy
    July 3, 2024
  • Triumphant Breakthrough: Security Forces Successfully Capture 4 Insurgents in Manipur Operation
    by adminitfy
    July 3, 2024

Welcome to the ultimate source for fresh perspectives! Explore curated content to enlighten, entertain and engage global readers.

  • Facebook
  • X
  • Instagram
  • LinkedIn

Latest Posts

  • Voyager 1 Reaches Historic One Light-Day Distance Milestone
  • India’s Crypto Taxation: Designing a Compliant, Competitive Web3 Regime
  • 50 Meghalaya Farmers Champion Responsible Aquaculture
  • Fitness Cert Shame: Toddler Leg Fracture Found 3 Days After Discharge
  • Manipur Liquor Tragedy: Death Toll Rises to 16, 600 Hospitalized
  • November 2026 (676)
  • October 2026 (646)
  • September 2026 (524)
  • August 2026 (1001)
  • July 2026 (986)
  • June 2026 (963)
  • May 2026 (922)
  • April 2026 (1525)
  • March 2026 (1522)
  • February 2026 (1252)
  • January 2026 (968)
  • December 2025 (942)
  • November 2025 (853)
  • October 2025 (869)
  • September 2025 (733)
  • August 2025 (810)
  • July 2025 (720)
  • June 2025 (1244)
  • May 2025 (2201)
  • April 2025 (1481)
  • March 2025 (2020)
  • February 2025 (1159)
  • January 2025 (1440)
  • December 2024 (1499)
  • November 2024 (1771)
  • October 2024 (1815)
  • September 2024 (1750)
  • August 2024 (1458)
  • July 2024 (1268)

Contact

Email

info@itfy.in

Location

INDIA

Copyright 2026 — Itfy.in. All rights reserved.